198 related articles for article (PubMed ID: 7942680)
1. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.
Sampliner RE
Am J Gastroenterol; 1994 Oct; 89(10):1844-8. PubMed ID: 7942680
[TBL] [Abstract][Full Text] [Related]
2. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Sharma P; Sampliner RE; Camargo E
Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
[TBL] [Abstract][Full Text] [Related]
3. Squamous islands in Barrett's esophagus: what lies underneath?
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1998 Mar; 93(3):332-5. PubMed ID: 9517634
[TBL] [Abstract][Full Text] [Related]
4. High power setting argon plasma coagulation for the eradication of Barrett's esophagus.
Pereira-Lima JC; Busnello JV; Saul C; Toneloto EB; Lopes CV; Rynkowski CB; Blaya C
Am J Gastroenterol; 2000 Jul; 95(7):1661-8. PubMed ID: 10925965
[TBL] [Abstract][Full Text] [Related]
5. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
6. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
7. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3420-6. PubMed ID: 10606297
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression.
Kahaleh M; Van Laethem JL; Nagy N; Cremer M; Devière J
Endoscopy; 2002 Dec; 34(12):950-5. PubMed ID: 12471537
[TBL] [Abstract][Full Text] [Related]
9. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
Ouatu-Lascar R; Triadafilopoulos G
Am J Gastroenterol; 1998 May; 93(5):711-6. PubMed ID: 9625114
[TBL] [Abstract][Full Text] [Related]
10. Preferential repair by squamous epithelium of thermal induced injury to the proximal stomach in patients undergoing ablation of Barrett's esophagus.
Fass R; Garewal HS; Hayden CW; Ramsey L; Sampliner RE
Gastrointest Endosc; 2001 Jun; 53(7):711-6. PubMed ID: 11375576
[TBL] [Abstract][Full Text] [Related]
11. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
[TBL] [Abstract][Full Text] [Related]
12. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study.
Ortner M-; Zumbusch K; Liebetruth J; Ebert B; Fleige B; Dietel M; Lochs H
Endoscopy; 2002 Aug; 34(8):611-6. PubMed ID: 12173080
[TBL] [Abstract][Full Text] [Related]
13. Maximal acid reflux control for Barrett's oesophagus: feasible and effective.
Srinivasan R; Katz PO; Ramakrishnan A; Katzka DA; Vela MF; Castell DO
Aliment Pharmacol Ther; 2001 Apr; 15(4):519-24. PubMed ID: 11284781
[TBL] [Abstract][Full Text] [Related]
14. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
15. Relationship between rate of change in acid exposure along the esophagus and length of Barrett's epithelium.
Tharalson EF; Martinez SD; Garewal HS; Sampliner RE; Cui H; Pulliam G; Fass R
Am J Gastroenterol; 2002 Apr; 97(4):851-6. PubMed ID: 12003418
[TBL] [Abstract][Full Text] [Related]
16. Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus.
Sampliner RE; Camargo L; Fass R
Am J Gastroenterol; 2002 Feb; 97(2):270-2. PubMed ID: 11866260
[TBL] [Abstract][Full Text] [Related]
17. Histological and anatomic changes in Barrett's esophagus after antireflux surgery.
Low DE; Levine DS; Dail DH; Kozarek RA
Am J Gastroenterol; 1999 Jan; 94(1):80-5. PubMed ID: 9934735
[TBL] [Abstract][Full Text] [Related]
18. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.
Gurski RR; Peters JH; Hagen JA; DeMeester SR; Bremner CG; Chandrasoma PT; DeMeester TR
J Am Coll Surg; 2003 May; 196(5):706-12; discussion 712-3. PubMed ID: 12742201
[TBL] [Abstract][Full Text] [Related]
19. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Haber M
Am J Gastroenterol; 1996 Sep; 91(9):1758-65. PubMed ID: 8792694
[TBL] [Abstract][Full Text] [Related]
20. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
Menges M; Müller M; Zeitz M
Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
